A Phase 2 interventional study of Orelabrutinib High dose and Orelabrutinib Low dose in Mantle Cell Lymphoma, sponsored by InnoCare Pharma Inc.. Completed at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by InnoCare Pharma Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Lymphoma, Mantle-Cell with a site in China — 44 open to participants now, 56 under way, 10 of them phase 3. Lymphoma, Mantle-Cell · China.
Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, this one is the 55th largest by enrollment of the 91 interventional ones that give a count, is one of 6 that started in 2023, is one of 31 in phase 2, and was the 61st registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →44 of the 98 studies in Lymphoma, Mantle-Cell with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18+
Guangzhou Lupeng Pharmaceutical Company LTD. · Sites in China
Ages 18+
Ascentage Pharma Group Inc. · Sites in China, United States
Ages 18+
Guangzhou Lupeng Pharmaceutical Company LTD. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 55 · Phase 3 15 · Phase 4 2
First in 2008; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 50 across the 91 interventional studies, 60 across the 7 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under InnoCare Pharma Inc., one of the names counted as InnoCare Pharma Limited. Under that name alone:
InnoCare Pharma Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
InnoCare Pharma Limited has 6 studies filed under Lymphoma, Mantle-Cell — fewer than ten, so there is no comparison to draw.
12 of the studies in Lymphoma, Mantle-Cell with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT02972840Phase 3Acerta Pharma BVA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | 2027-02-15 |
| NCT06496308Phase 3Ruijin HospitalBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | 2027-07-10 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT06852638RenJi HospitalCD70-targeted immunoPET Imaging of Malignant Cancers | 2026-12-23 |
Add all 12 to your calendar (.ics) → With an account.
Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma to Evaluate the Efficacy and Safety in Mantle Cell Lymphoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Orelabrutinib High dose
Drug: Orelabrutinib Low dose
Orelabrutinib will be administered as 3 tablets once per day
Orelabrutinib will be administered as 1 tablet once per day
Objective response rate(ORR)
Proportion of subjects with tumor response of Complete Response(CR) or Partial Response(PR) after treatment in total subjects.
Time frame: Through study completion, an average of 2 year
Complete Response Rate (CRR)
The proportion of subjects with tumor response of Complete Response(CR) after treatment in total subjects.
Time frame: Through study completion, an average of 2 year
Progression-Free Survival (PFS)
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first.
Time frame: Through study completion, an average of 2 year
Duration of Response (DoR)
The time from documentation of objective response to the first occurrence of tumor progression or death due to any cause, whichever occurs first.
Time frame: Through study completion, an average of 2 year
Maximum concentration (Cmax,ss)
Time frame: Predose up to 24 hours postdose
Time to maximum concentration (Tmax)
Time frame: Predose up to 24 hours postdose
Area under the plasma concentration-time curve (AUC)
Time frame: Predose up to 24 hours postdose
Half-life (T1/2)
Time frame: Predose up to 24 hours postdose
Apparent clearance (CL/F)
Time frame: Predose up to 24 hours postdose
Adverse events(AEs)
Time frame: Through study completion, an average of 2 year
Serious adverse events (SAEs)
Time frame: Through study completion, an average of 2 year
Ran from Aug 2023 to primary completion in Dec 2024, 15 months.
Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 15 months is below that.
Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.